Commerzbank Aktiengesellschaft’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.25M | Sell |
41,571
-13,185
| -24% | -$1.74M | 0.1% | 91 |
|
|
2026
Q1 | $7.63M | Sell |
54,756
-11,222
| -17% | -$1.57M | 0.16% | 69 |
|
|
2025
Q4 | $8.1M | Buy |
65,978
+53,507
| +429% | +$6.5M | 0.16% | 72 |
|
|
2025
Q3 | $1.39M | Buy |
+12,471
| New | +$1.42M | 0.03% | 187 |
|
|
2025
Q2 | – | Sell |
-13,326
| Closed | -$1.49M | – | 359 |
|
|
2025
Q1 | $1.49M | Buy |
13,326
+2,863
| +27% | +$295K | 0.03% | 142 |
|
|
2024
Q4 | $963K | Buy |
10,463
+464
| +5% | +$41.8K | 0.02% | 152 |
|
|
2024
Q3 | $838K | Sell |
9,999
-10,337
| -51% | -$789K | 0.02% | 151 |
|
|
2024
Q2 | $1.4M | Buy |
20,336
+12,680
| +166% | +$846K | 0.05% | 103 |
|
|
2024
Q1 | $561K | Buy |
7,656
+3,000
| +64% | +$231K | 0.02% | 145 |
|
|
2023
Q4 | $378K | Buy |
+4,656
| New | +$362K | 0.02% | 135 |
|
|
2022
Q4 | – | Sell |
-8,265
| Closed | -$510K | – | 131 |
|
|
2022
Q3 | $510K | Buy |
+8,265
| New | +$521K | 0.04% | 84 |
|
|
2020
Q3 | – | Sell |
-63,586
| Closed | -$4.89M | – | 102 |
|
|
2020
Q2 | $4.89M | Sell |
63,586
-134,855
| -68% | -$10.3M | 0.52% | 27 |
|
|
2020
Q1 | $14.8M | Buy |
198,441
+2,557
| +1% | +$177K | 0.66% | 35 |
|
|
2019
Q4 | $12.7M | Sell |
195,884
-89,997
| -31% | -$5.86M | 0.12% | 123 |
|
|
2019
Q3 | $18.1M | Sell |
285,881
-14,749
| -5% | -$964K | 0.14% | 129 |
|
|
2019
Q2 | $20.3M | Sell |
300,630
-69,384
| -19% | -$4.56M | 0.16% | 114 |
|
|
2019
Q1 | $24.1M | Sell |
370,014
-68,675
| -16% | -$4.56M | 0.22% | 94 |
|
|
2018
Q4 | $27.4M | Sell |
438,689
-105,343
| -19% | -$7.36M | 0.28% | 69 |
|
|
2018
Q3 | $42M | Buy |
544,032
+118,352
| +28% | +$8.94M | 0.36% | 63 |
|
|
2018
Q2 | $30.2M | Buy |
425,680
+43,815
| +11% | +$3.09M | 0.29% | 76 |
|
|
2018
Q1 | $28.8M | Sell |
381,865
-33,736
| -8% | -$2.68M | 0.3% | 76 |
|
|
2017
Q4 | $29.8M | Sell |
415,601
-32,152
| -7% | -$2.44M | 0.34% | 66 |
|
|
2017
Q3 | $36.3M | Buy |
447,753
+87,022
| +24% | +$6.65M | 0.48% | 42 |
|
|
2017
Q2 | $25.5M | Sell |
360,731
-167,047
| -32% | -$11.1M | 0.43% | 57 |
|
|
2017
Q1 | $35.8M | Sell |
527,778
-120,243
| -19% | -$8.46M | 0.53% | 40 |
|
|
2016
Q4 | $46.4M | Buy |
648,021
+16,521
| +3% | +$1.23M | 0.68% | 30 |
|
|
2016
Q3 | $50M | Sell |
631,500
-388,659
| -38% | -$31.6M | 0.81% | 25 |
|
|
2016
Q2 | $85.1K | Buy |
1,020,159
+365,079
| +56% | +$32.4M | 0.57% | 39 |
|
|
2016
Q1 | $60.2M | Sell |
655,080
-876,558
| -57% | -$79M | 0.5% | 41 |
|
|
2015
Q4 | $155M | Buy |
1,531,638
+75,328
| +5% | +$7.84M | 1.19% | 15 |
|
|
2015
Q3 | $143M | Buy |
1,456,310
+45,013
| +3% | +$5M | 1.07% | 22 |
|
|
2015
Q2 | $165M | Sell |
1,411,297
-201,963
| -13% | -$22.1M | 0.87% | 24 |
|
|
2015
Q1 | $158M | Buy |
1,613,260
+203,264
| +14% | +$20.6M | 0.95% | 22 |
|
|
2014
Q4 | $133M | Sell |
1,409,996
-212,448
| -13% | -$22M | 0.85% | 24 |
|
|
2014
Q3 | $173M | Buy |
1,622,444
+429,143
| +36% | +$42M | 0.7% | 26 |
|
|
2014
Q2 | $98.9M | Buy |
1,193,301
+200,386
| +20% | +$15.6M | 0.51% | 38 |
|
|
2014
Q1 | $70.4M | Buy |
992,915
+16,570
| +2% | +$1.3M | 0.3% | 55 |
|
|
2013
Q4 | $78.7M | Sell |
976,345
-828,839
| -46% | -$57.7M | 0.39% | 49 |
|
|
2013
Q3 | $113M | Buy |
1,805,184
+332,620
| +23% | +$19.9M | 0.57% | 37 |
|
|
2013
Q2 | $75.5M | Buy |
+1,472,564
| New | +$76.8M | 0.33% | 57 |
|
Other funds holding GILD
N
Commerzbank Aktiengesellschaft's GILD Position: Q2 2026 in Review
Commerzbank Aktiengesellschaft reduced its Gilead Sciences (GILD) stake by 24% in Q2 2026, selling an estimated $1.74M and leaving 41,571 shares worth $5.25M. The position accounts for 0.1% of the portfolio, ranked #91.
Commerzbank Aktiengesellschaft first reported a position in GILD in Q2 2013 and has held it in 40 quarters since. The position peaked at $173M in Q3 2014. 1,535 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Commerzbank Aktiengesellschaft held 41,571 shares of Gilead Sciences worth $5.25M as of Q2 2026.
- Commerzbank Aktiengesellschaft sold 13,185 Gilead Sciences shares in Q2 2026, an estimated $1.74M.
- Gilead Sciences made up 0.1% of Commerzbank Aktiengesellschaft's portfolio in Q2 2026, its #91 holding.
- Commerzbank Aktiengesellschaft first reported a position in Gilead Sciences in Q2 2013 and has held it in 40 quarters since.
- Commerzbank Aktiengesellschaft's Gilead Sciences position peaked at $173M in Q3 2014.
- 1,535 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Commerzbank Aktiengesellschaft's 13F filing for Q2 2026, filed 7 Aug 2026.